4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline,
icotinib,
Icotinib,
610798-31-7,
Conmana,
BPI-2009,
BPI-2009H,
UNII-9G6U5L461Q,
N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine,
CHEMBL2087361,
BPI2009,
9G6U5L461Q,
N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine,
Lcotinib,
Icotinib(Lcotinib),
icotinib,BPI-2009H,
GTPL7641,
SCHEMBL5843603,
DTXSID20209952,
EX-A306,
QQLKULDARVNMAL-UHFFFAOYSA-N,
HMS3651F12,
BCP21716,
BPI 2009,
2468AH,
BDBM50391089,
HY-15164A,
MFCD22124501,
s2922,
ZINC43207566,
AKOS030231301,
DB11737,
SB16602,
4CA-0630,
AK547890,
SC-94666,
FT-0701617,
SW219698-1,
Z-3130,
(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-,
(3-Ethynyl-phenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine,
Icotinib Hydrochloride,
C22H21N3O4,
ACN-037795,
CS-2017,
B1496,
A13825,
C531470,
Icotinib, 98%, a potent EGFR inhibitor - 25MG 25mg,
4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline,
1204313-51-8,
N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine,